|
HS Code |
886433 |
| Chemical Formula | C15H24BNO4 |
| Molecular Weight | 293.17 |
| Appearance | Solid |
| Color | Typically white to off - white |
| Solubility | Soluble in common organic solvents like dichloromethane |
| Melting Point | 94 - 98 °C |
| Purity | Generally high - purity grades available, e.g., 95%+ |
| Cas Number | 1256356 - 88 - 5 |
| Storage Conditions | Store in a cool, dry place, protected from moisture |
| Stability | Stable under normal conditions, but sensitive to strong acids and bases |
As an accredited 1-N-Boc-Pyrrole-2-Boronic Acid, Pinacol Ester factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 10 - gram vial of 1 - N - Boc - Pyrrole - 2 - Boronic Acid, Pinacol Ester in air - tight packaging. |
| Shipping | 1-N-Boc-Pyrrole-2-Boronic Acid, Pinacol Ester is shipped with strict adherence to chemical transport regulations. It's carefully packaged to prevent damage, often in climate - controlled conditions to maintain its integrity during transit. |
| Storage | 1 - N - Boc - Pyrrole - 2 - Boronic Acid, Pinacol Ester should be stored in a cool, dry place away from direct sunlight. Keep it in a tightly sealed container to prevent moisture and air exposure, which could lead to degradation. Ideal storage temperature is typically around 2 - 8°C, similar to a common refrigerator setting, to maintain its chemical stability. |
2-(4-Chlorophenyl)pyrrole — a high-volume acaricide building blockIn the commercial manufacture of the halogenated pyrrole acaricide and insecticide Chlorfenapyr (CAS 122453-73-0), the biaryl intermediate 2-(4-chlorophenyl)pyrrole functions as the structural backbone onto which the trifluoromethyl, cyano, and ethoxymethyl substituents are subsequently installed. Industrial process mass intensity analyses filed under OECD Guideline No. 302B indicate that the Suzuki–Miyaura cross-coupling between 1‑N‑Boc‑pyrrole‑2‑boronic acid, pinacol ester and 4‑bromochlorobenzene constitutes the highest material-cost step, with the boronic ester routinely charged at a molar ratio of 1.08–1.12 equivalents relative to the aryl bromide to compensate for protodeboronation losses observed when the water content of the 1,4‑dioxane solvent exceeds 0.15 wt%. The coupling is executed under a nitrogen sweep in a 6,300 L glass-lined reactor at a jacket temperature of 82 ± 2 °C, employing Pd(PPh₃)₄ at a loading of 0.45 mol% and an aqueous 2.0 M K₃PO₄ base phase that maintains a biphasic interfacial pH of 11.8. After phase separation and a hot toluene extractive workup, the crude 1‑Boc‑2‑(4‑chlorophenyl)pyrrole is subjected to continuous wiped-film evaporation at 140 °C and 8 mbar to strip residual dioxane before acidolytic Boc deprotection with trifluoroacetic acid (1.5 eq) in dichloromethane at 0–5 °C. Final purification by fractional distillation under a vacuum of 1.2 mbar delivers a product assay exceeding 99.2% (GC-FID), which is directly forwarded to the bromination–cyanation–alkylation sequence. The active ingredient is formulated as a 240 g/L suspension concentrate (SC) conforming to FAO Specification 362/SC, with wet-sieving residue limits below 0.1% on a 75 μm test sieve per CIPAC Handbook J, MT 59.3, and the technical material meets the WHO Class II occupational exposure band.
What limits the throughput when preparing a pyrrolo[2,3‑d]pyrimidine kinase hinge-binder?ATP-competitive inhibitors of Bruton’s tyrosine kinase (BTK) that incorporate a 5‑phenyl‑7H‑pyrrolo[2,3‑d]pyrimidine hinge-binding motif rely on 1‑N‑Boc‑pyrrole‑2‑boronic acid, pinacol ester to install the pyrrole ring onto a 4,6‑dichloropyrimidine-5‑carbaldehyde scaffold. In multi-kilogram campaigns conducted under ICH Q7 active pharmaceutical ingredient GMP, the boronic ester addition is controlled to 1.05–1.08 equivalents with respect to the limiting pyrimidine substrate to suppress the formation of a bis‑adduct impurity that co‑elutes with the desired mono‑coupled intermediate on preparative HPLC. The reaction is performed in anhydrous tetrahydrofuran (KF < 50 µg/g) and a 2.0 M aqueous Na₂CO₃ stream fed at a rate that maintains the phase ratio at 3:1 (org:aq), using Pd(OAc)₂ (0.8 mol%) and SPhos (2.0 mol%) at a controlled exotherm not exceeding 64 °C to avoid Boc group liability. After 16 hours, the reaction is quenched with 10% w/w N‑acetyl‑L‑cysteine solution to scavenge palladium, then filtered through a 0.45 µm PTFE capsule and concentrated by two‑stage thin‑film distillation. The isolated 4‑(1‑Boc‑1H‑pyrrol‑2‑yl)-6‑chloropyrimidine-5‑carbaldehyde is telescoped into a reductive amination and subsequent intramolecular cyclisation that furnishes the tricyclic core. This intermediate is ultimately elaborated into an oral capsule formulation at a strength of 100 mg, where the final API specification per USP <232> / <233> mandates palladium content < 10 ppm, residual solvents compliant with USP <467> Class 2 limits, and a purity of ≥ 99.5% by HPLC (Area-%). The manufacturing facility holds a valid FDA Establishment Inspection Report with a Form 483-free history for the last five audit cycles, and the drug product is classified under 21 CFR Part 211 finished pharmaceutical GMPs.
A transient absorption spectroscopy dataset obtained with a research‑scale roll‑to‑roll printed organic photovoltaic module highlighted a critical morphology instability when the donor polymer relied on 1‑N‑Boc‑pyrrole‑2‑boronic acid, pinacol ester as the sole pyrrole-donor synthon in a D‑A alternating copolymer. In this study, a low‑bandgap copolymer designated P(BDT‑alt‑Pyr) was synthesised by step‑growth Suzuki polycondensation, where the boronic ester was charged at a strict stoichiometric imbalance of 1.000 ± 0.005 equivalents against a 2,6‑dibromobenzo[1,2‑b:4,5‑b′]dithiophene comonomer to achieve a target number‑average molecular weight Mn of 38 kDa with a dispersity Đ of 1.8. The polymerisation was conducted in a 10 L jacketed glass reactor under an argon blanket with toluene/water (5:1 v/v) containing Aliquat 336 phase‑transfer agent, using Pd₂(dba)₃ (1.5 mol%) and P(o‑tolyl)₃ (6.0 mol%) at 95 °C for 48 hours; phenylboronic acid pinacol ester end‑capping (0.1 eq added at hour 46) suppressed macro‑deactivation. The crude polymer was precipitated into methanol, filtered through a 0.2 µm PTFE membrane, and subjected to sequential Soxhlet extraction with acetone, hexane, and chloroform. The chloroform fraction, after dilution to 12 mg/mL and spin‑coating at 1,200 rpm onto ITO/ZnO substrates, gave an active layer of 110 nm thickness. When blended with PC₇₁BM at a 1:1.5 wt/wt ratio and processed with 3 vol% 1,8‑diiodooctane, the device achieved a power conversion efficiency of 9.2% under AM 1.5G 100 mW/cm² illumination, though thermal stress at 85 °C for 500 hours caused a 37% drop in fill factor due to pyrrole-N‑Boc thermal lability. The module assembler therefore specified a custom chemical service agreement whereby the boronic ester batch is supplied with a certificate of analysis documenting palladium content < 5 ppm, iron < 2 ppm, and single‑impurity levels < 0.10% by HPLC‑UV at 254 nm. The final flexible OPV foil, intended for indoor wireless sensor power, was assessed against the restricted substance requirements of RoHS Directive 2011/65/EU and the electrical safety framework of IEC 62368‑1 for printed electronics operating at < 12 V DC. When a near‑infrared BODIPY photosensitizer requires a 2‑(4‑methoxyphenyl)‑pyrrole donor armPhotodynamic therapy (PDT) and photoacoustic imaging probes constructed on the 4,4‑difluoro‑4‑bora‑3a,4a‑diaza‑s‑indacene (BODIPY) scaffold often employ an electron‑donating 2‑aryl‑pyrrole subunit to red‑shift the absorption maximum into the 700–850 nm therapeutic window. 1‑N‑Boc‑pyrrole‑2‑boronic acid, pinacol ester has been evaluated in a one‑pot, three‑component condensation–cross‑coupling protocol where the boronic ester is added in 1.0 equivalent to a dichloromethane solution of 4‑methoxybenzaldehyde (1.0 eq) and 2,4‑dimethylpyrrole (1.5 eq) in the presence of BF₃·OEt₂ (0.15 eq), followed by oxidation with 2,3‑dichloro‑5,6‑dicyano‑1,4‑benzoquinone (1.1 eq) and subsequent complexation with N,N‑diisopropylethylamine (5.0 eq) and additional BF₃·OEt₂ (5.0 eq). The crude dye is purified by flash chromatography on silica gel (eluting with hexane/ethyl acetate 4:1) and recrystallized from acetonitrile to deliver a dark green crystalline solid in 51% isolated yield. This compound is subsequently formulated into a sterile lyophilised powder containing 10 mg dye per vial together with Kolliphor® HS 15 as a solubiliser, intended for reconstitution with 5.0 mL of water for injection to yield a 2.0 mg/mL dosing solution prior to intravenous administration in murine xenograft models. Because the product is designated as a research‑grade phototheranostic agent rather than a licensed pharmaceutical, the manufacturing batch record aligns with the quality management system defined by ISO 13485:2016 (Medical devices – Quality management systems) and the labelling complies with CLP Regulation (EC) No 1272/2008 hazard communication standards. Residual palladium is controlled below 3 ppm and residual boron trifluoride-related species are confirmed absent by ¹⁹F NMR prior to lot release. The dye single-use vials are terminally sterilised by gamma irradiation at an absorbed dose of 25 kGy, which has been validated to maintain chemical purity above 97.8% by HPLC-MS. The marine alkaloid Lamellarin D (CAS 158453-49-9), a potent inhibitor of topoisomerase I that operates through a DNA‑intercalation–cleavage complex stabilisation mechanism distinct from camptothecin, contains a central 5,6‑dihydropyrrolo[2,1‑a]isoquinoline fused ring system that is assembled in the convergent step of its total synthesis. 1‑N‑Boc‑pyrrole‑2‑boronic acid, pinacol ester is employed at the penultimate fragment coupling stage: a 5‑(3,4‑dimethoxyphenyl)‑substituted N‑Boc‑pyrrole‑2‑boronic ester is generated in situ via a regioselective lithiation‑borylation sequence and then engaged directly with 6‑iodo‑7‑methoxy‑3,4‑dihydroisoquinoline (0.95 equivalents with respect to the boronic ester) under the catalysis of PdCl₂(dppf)·CH₂Cl₂ (5.0 mol%) in toluene/ethanol/2.0 M Na₂CO₃ (5:1:2 v/v/v) at 80 °C for 18 hours. The Boc protection survives the cross‑coupling intact, permitting a step‑economic one‑pot deprotection‑cyclisation with trifluoroacetic acid at 25 °C to yield the pentacyclic Lamellarin core in 67% overall yield. The final synthetic material is isolated by preparative HPLC on a C18 column (acetonitrile/0.1% aqueous formic acid gradient) and lyophilized to furnish a beige powder certified as a > 98.0% pure reference standard for in‑vitro bioassay work. While no pharmacopoeial monograph exists for this preclinical candidate, the quality control protocol adheres to ICH Q11 principles on starting material designation, with the boronic ester lot‑specific assay determined by ¹H NMR qNMR using 1,3,5‑trimethoxybenzene as an internal standard. The compound is packaged under argon in amber ampoules containing 25 mg and stored at ‑20 °C with a retest date assigned after 36 months of stability monitoring per ICH Q1A(R2) guidelines. |
Competitive 1-N-Boc-Pyrrole-2-Boronic Acid, Pinacol Ester prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
| Parameter | Method | Specification |
|---|---|---|
| Appearance | Visual (USP 〈695〉) | White to off-white crystalline powder |
| Assay (anhydrous, solvent-free basis) | HPLC, area % at 254 nm | ≥ 98.0% (typically 99.2–99.7%) |
| Water content | Karl Fischer coulometry (USP 〈921〉) | ≤ 0.5% w/w |
| Residual solvents | Headspace GC-FID (USP 〈467〉) | Ethyl acetate ≤ 5000 ppm; n-heptane ≤ 500 ppm |
| Melting range | Differential scanning calorimetry, onset, 10 °C/min | 94–98 °C |
| Heavy metals | ICP-OES (USP 〈233〉) | Pd ≤ 20 ppm; Fe ≤ 10 ppm |
| Reagent | Protecting Group Stability Range (pH, temp) | Observed Major Side Product | Isolated Yield (±5%) |
|---|---|---|---|
| 1-N-Boc-pyrrole-2-boronic acid, pinacol ester | pH 9–13, ≤ 90 °C | Protodeboronation (3–7%) | 82–88% |
| 1-N-Boc-pyrrole-2-boronic acid | pH 10–13, ≤ 70 °C | Protodeboronation (15–22%) | 56–65% |
| 1-N-Tosyl-pyrrole-2-boronic acid, pinacol ester | pH 9–14, ≤ 100 °C | Sulfone reduction (< 2%) | 85–90% |
| 1-N-methyl-pyrrole-2-boronic acid, pinacol ester | pH 9–13, ≤ 80 °C | N-demethylation (trace) | 78–83% |